Oxaliplatin + Capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms, Unknown Primary
Conditions
Neoplasms, Unknown Primary
Trial Timeline
Sep 1, 2004 → Jan 1, 2009
NCT ID
NCT00193609About Oxaliplatin + Capecitabine
Oxaliplatin + Capecitabine is a phase 2 stage product being developed by Roche for Neoplasms, Unknown Primary. The current trial status is completed. This product is registered under clinical trial identifier NCT00193609. Target conditions include Neoplasms, Unknown Primary.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00193609 | Phase 2 | Completed |
Competing Products
20 competing products in Neoplasms, Unknown Primary
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| LY4337713 | Eli Lilly | Phase 1 | 33 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 77 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 25 |
| GEMZAR + ALIMTA | Eli Lilly | Phase 3 | 77 |